Comprehensive and up-to-date review of the molecular basis of cancer
Cutting-edge insights from genomics, proteomics, and new chemoprevention strategies
Includes discussion of new therapeutic monoclonal antibodies
Coverage of new cytotoxic or cytostatic small-molecular-weight compounds
Deillegalscription of emerging molecular targets and current drugs under development
Multidisciplinary perspective by recognized authorities from across the US and Europe
Comprehensive and up-to-date review of the molecular basis of cancer
Cutting-edge insights from genomics, proteomics, and new chemoprevention strategies
Includes discussion of new therapeutic monoclonal antibodies
Coverage of new cytotoxic or cytostatic small-molecular-weight compounds
Deillegalscription of emerging molecular targets and current drugs under development
Multidisciplinary perspective by recognized authorities from across the US and Europe
Includes supplementary material: sn.pub/extras
Drawing on years of significant scientific advances and clinical developments, the editors of this third edition of Principles of Molecular Oncology have thoroughly updated the highly praised first and second editions and added new chapters to reflect the knowledge emerging from research on genomics, proteomics, chemoprevention strategies, pharmacogenomics, new molecular targets, therapeutic monoclonal antibodies, and innovative cytotoxic and cytostatic small molecular-weight molecules. Comprehensive and intellectually stimulating, this book not only clearly elucidates the fundamentals of this dramatically advancing field, but also interprets the vast and often complex molecular data available. It fills a much neglected gap between information and knowledge, and holds out the hope of new anticancer strategies that will reduce the process of carcinogenesis, cancer cell proliferation and significantly reduce metastasis.
Selecting the Right Targets for Cancer Therapy.- Clinical Importance of Prognostic Factors.- Genetic Markers in Sporadic Tumors.- Genetic Markers in Breast Tumors with Hereditary Predisposition.- Circulating Tumor Markers.- Antibody-Based Proteomics Analysis of Tumor Cell Signaling Pathways.- Gene Expression Arrays for Pathway Analysis in Cancer Research.- Signaling Pathways in Cancer.- Estrogen Receptor Pathways and Breast Cancer.- Cyclin-Dependent Kinases and Their Regulators as Potential Targets for Anticancer Therapeutics.- Angiogenesis Switch Pathways.- Apoptosis Pathways and New Anticancer Agents.- Genomic Instability, DNA Repair Pathways and Cancer.- Epigenomics and Cancer.- Harnessing the Power of Immunity to Battle Cancer: Much Ado about Nothing or All's Well That Ends Well?.- Aurora Kinases: A New Target for Anticancer Drug Development.- Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways.- Suicide Gene Therapy.- Genotypes That Predict Toxicity and Genotypes That Predict Efficacy of Anticancer Drugs.- A Personal Account of the Chemoprevention of Breast Cancer: Possible or Not Possible?.
Drawing on years of significant scientific advances and clinical developments, the editors of POMO III have thoroughly updated the highly praised first and second editions and added new chapters to reflect the knowledge emerging from research on genomics, proteomics, chemoprevention strategies, pharmacogenomics, new molecular targets, therapeutic monoclonal antibodies, and innovative cytotoxic and cytostatic small molecular-weight molecules. The first edition of this book (Humana Press, 2000) was also the first comprehensive presentation of the concept of cancer as a "disease process" involving key regulatory pathways. The second edition (2004) reaffirmed this dynamic concept, incorporating more recent evidence, and introducing such new topics of special interest as the combination of molecular diagnostics-expression profiling of genes and proteins- with developmental therapeutics, and the "binary state" concept (active/inactive) that seeks more relevant targets within the global molecular matrix of a given cancer. Comprehensive and intellectually stimulating, POMO III not only clearly elucidates the fundamentals of this dramatically advancing field, but also interprets the vast and often complex molecular data available. It fills a much neglected gap between "information" and "knowledge," and holds out the hope of new anticancer strategies that will reduce the process of carcinogenesis, cancer cell proliferation and significantly reduce metastasis.
From the reviews of the third edition:
"This is an update of a book of individual reviews of molecular oncology topics written by specialists in the field. ... The intention is to present a broad overview of the concepts in molecular medicine and tumor biology that form the basis of many ongoing drug discovery projects ... . The book is written for a broad audience, including students, house officers and clinical fellows, beginning researchers in cancer biology, and even practitioners of oncology." (Alexander C Minella, Doody´s Review Service, 2008)
"The book provides a comprehensive and in-depth view of molecular basis of cancer. ... it is a valuable resource of knowledge for both clinical and experimental oncologists. Those who are interested in the basic understanding of great progress which has been achieved in molecular oncology in last year will enjoy this book as well." (C. Altaner, Neoplasma, September, 2008)
Drawing on years of significant scientific advances and clinical developments, the editors of POMO III have thoroughly updated the highly praised first and second editions and added new chapters to reflect the knowledge emerging from research on genomics, proteomics, chemoprevention strategies, new molecular targets, therapeutic monoclonal antibodies, and innovative cytotoxic and cytostatic small molecular-weight molecules. The first edition of this book (Humana Press, 2000) was also the first comprehensive presentation of the concept of cancer as a "disease process" involving key regulatory pathways. The second edition (2004) reaffirmed this dynamic concept, incorporating more recent evidence, and introducing such new topics of special interest as the combination of molecular diagnostics--expression profiling of genes and proteins--with developmental therapeutics, and the "binary state" concept (active/inactive) that seeks more relevant targets within the global molecular matrix of a given cancer. Comprehensive and intellectually stimulating, POMO III not only clearly elucidates the fundamentals of this dramatically advancing field, but also interprets the vast and often complex molecular data available. It fills a much neglected gap between "information" and "knowledge", and holds out the hope of new anticancer strategies that will reduce cancer cell proliferation and significantly reduce metastasis.
From the reviews of the third edition:
"This is an update of a book of individual reviews of molecular oncology topics written by specialists in the field. ... The intention is to present a broad overview of the concepts in molecular medicine and tumor biology that form the basis of many ongoing drug discovery projects ... . The book is written for a broad audience, including students, house officers and clinical fellows, beginning researchers in cancer biology, and even practitioners of oncology." (Alexander C Minella, Doody's Review Service, 2008)
"The book provides a comprehensive and in-depth view of molecular basis of cancer. ... it is a valuable resource of knowledge for both clinical and experimental oncologists. Those who are interested in the basic understanding of great progress which has been achieved in molecular oncology in last year will enjoy this book as well." (C. Altaner, Neoplasma, September, 2008)
Inhaltsverzeichnis
Selecting the Right Targets for Cancer Therapy.- Clinical Importance of Prognostic Factors.- Genetic Markers in Sporadic Tumors.- Genetic Markers in Breast Tumors with Hereditary Predisposition.- Circulating Tumor Markers.- Antibody-Based Proteomics Analysis of Tumor Cell Signaling Pathways.- Gene Expression Arrays for Pathway Analysis in Cancer Research.- Signaling Pathways in Cancer.- Estrogen Receptor Pathways and Breast Cancer.- Cyclin-Dependent Kinases and Their Regulators as Potential Targets for Anticancer Therapeutics.- Angiogenesis Switch Pathways.- Apoptosis Pathways and New Anticancer Agents.- Genomic Instability, DNA Repair Pathways and Cancer.- Epigenomics and Cancer.- Harnessing the Power of Immunity to Battle Cancer: Much Ado about Nothing or All's Well That Ends Well?.- Aurora Kinases: A New Target for Anticancer Drug Development.- Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways.- Suicide Gene Therapy.- Genotypes That Predict Toxicity and Genotypes That Predict Efficacy of Anticancer Drugs.- A Personal Account of the Chemoprevention of Breast Cancer: Possible or Not Possible?.
Klappentext
Drawing on years of significant scientific advances and clinical developments, the editors of POMO III have thoroughly updated the highly praised first and second editions and added new chapters to reflect the knowledge emerging from research on genomics, proteomics, chemoprevention strategies, new molecular targets, therapeutic monoclonal antibodies, and innovative cytotoxic and cytostatic small molecular-weight molecules. The first edition of this book (Humana Press, 2000) was also the first comprehensive presentation of the concept of cancer as a ¿disease process¿ involving key regulatory pathways. The second edition (2004) reaffirmed this dynamic concept, incorporating more recent evidence, and introducing such new topics of special interest as the combination of molecular diagnostics--expression profiling of genes and proteins--with developmental therapeutics, and the ¿binary state¿ concept (active/inactive) that seeks more relevant targets within the global molecular matrix of a given cancer. Comprehensive and intellectually stimulating, POMO III not only clearly elucidates the fundamentals of this dramatically advancing field, but also interprets the vast and often complex molecular data available. It fills a much neglected gap between ¿information¿ and ¿knowledge¿, and holds out the hope of new anticancer strategies that will reduce cancer cell proliferation and significantly reduce metastasis.
Drawing on years of significant scientific advances and clinical developments, the editors of this third edition of Principles of Molecular Oncology have thoroughly updated the highly praised first and second editions and added new chapters to reflect the knowledge emerging from research on genomics, proteomics, chemoprevention strategies, pharmacogenomics, new molecular targets, therapeutic monoclonal antibodies, and innovative cytotoxic and cytostatic small molecular-weight molecules. Comprehensive and intellectually stimulating, this book not only clearly elucidates the fundamentals of this dramatically advancing field, but also interprets the vast and often complex molecular data available. It fills a much neglected gap between information and knowledge, and holds out the hope of new anticancer strategies that will reduce the process of carcinogenesis, cancer cell proliferation and significantly reduce metastasis.
